Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial (DREAMtherapy)

This study has been terminated.
(2 DLTs had been reported from first 4 patients on lowest possible dose cohort.)
Sponsor:
Collaborators:
Cancer Research UK
AstraZeneca
Information provided by (Responsible Party):
Suzanne Rowland, Christie Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01160926
First received: July 7, 2010
Last updated: October 11, 2013
Last verified: October 2013
  Purpose

To determine the maximum tolerated dose (MTD) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.


Condition Intervention Phase
Rectal Cancer
Drug: AZD6244
Drug: Cediranib (AZD2171)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy

Resource links provided by NLM:


Further study details as provided by Christie Hospital NHS Foundation Trust:

Primary Outcome Measures:
  • To determine the MTD (maximum tolerated dose) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer. [ Time Frame: At point of surgery (10-12 weeks post treatment) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Grade 3 or 4 toxicity [ Time Frame: Up to point of surgery and long-term effects monitored for 3 years post treatment ] [ Designated as safety issue: Yes ]
  • Radiotherapy compliance [ Time Frame: for the 5 weeks of chemoradiotherapy ] [ Designated as safety issue: No ]
  • MRI (Magnetic Resonance Imaging)Response Rate [ Time Frame: 8 weeks post chemoradiation - at point of MRI scan ] [ Designated as safety issue: No ]
  • Histologically confirmed R0 resection rate [ Time Frame: 10-12 weeks post chemoradiation - at time of surgery ] [ Designated as safety issue: No ]
  • Pathological Complete Response (pCR) [ Time Frame: 10-12 weeks post chemoradiation - at point of surgery ] [ Designated as safety issue: No ]
  • Morbidity - post operative and long term [ Time Frame: 3 years post chemoradiation ] [ Designated as safety issue: No ]
  • To explore biological and radiological markers of response or toxicity [ Time Frame: Various timepoints up to point of surgery ] [ Designated as safety issue: No ]

    Tissue samples - from diagnostic sample, biopsy 6-8 days after single agent AZD6244/Cediranib and resection sample from surgery.

    Blood samples - screening, weeks 1, 3 and 5 during chemoradiotherapy and 8 weeks post chemoradiotherapy.

    FLT-PET scans - patients in AZD6244 cohorts only - at screening, after 10 days of dosing with single agent AZD6244 and 2 weeks post chemoradiation DCE-MRI scans - patients in both groups - at screening, after 10 days of dosing with single agent AZD6244/Cediranib and 2 weeks post chemoradiation



Enrollment: 31
Study Start Date: July 2010
Estimated Study Completion Date: December 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZD6244 + capecitabine + radiotherapy
10 days single-agent dosing AZD6244 Then 35 days dosing of AZD6244 in combination with standard chemoradiotherapy
Drug: AZD6244

Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd

Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy

Other Name: AZD6244
Experimental: Cediranib + capecitabine + radiotherapy
10 days single agent dosing with Cediranib (AZD2171) then 35 days dosing of AZD2171 in combination with standard chemoradiotherapy
Drug: Cediranib (AZD2171)

10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od

Oral tablets

Other Name: AZD2171

Detailed Description:

The best curative resection rates reported for patients with operable rectal cancer treated with standard chemoradiotherapy are approximately 50-60%.The pathological complete response rates are only 10-20%. Therefore, there is a need for more effective treatment. In this trial we will evaluate the combination of chemoradiotherapy with either a VEGFR (vascular endothelial growth factor receptor) or MEK (MAP Kinase)inhibitor.

Aims

  1. Define the tolerability, MTD (maximum tolerated dose) and DLT (dose limiting toxicities) of chemoradiotherapy in combination with

    • cediranib, a VEGF receptor tyrosine kinase inhibitor that inhibits angiogenesis or
    • AZD6244, a potent MEK inhibitor that inhibits cell proliferation
  2. Define a dose suitable for phase II evaluation
  3. Test the impact of the combination on soluble and imaging (FLT-PET and DCEMRI/DWI) biomarkers to guide their use in phase II testing Summary Patients will receive standard chemoradiotherapy plus ascending doses of AZD6244 or cediranib from day -10 (relative to start of chemoradiotherapy) to day 35. If feasible, patients' tumours will be resected 10-12 weeks after treatment. Translational studies on available tissue and blood will be performed and DCE-MRI/DWI and FLT-PET will be carried out on 5 patients in the expanded cohort for AZD6244 (FLT-PET and DCE-MRI) and 5 patients in the expanded cohort for cediranib (DCE-MRI).

Cohorts Cediranib - 15mg od, 20mg od and 30mg od AZD6244 - 50mg bd and 75mg bd

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inc Criteria:

  • Histologically confirmed rectal adenocarcinoma
  • MRI (magnetic resonance imaging) and triphasic CT (computerised tomography) defined locally advanced rectal cancer:

    • Mesorectal fascia involved or
    • Mesorectal fascia threatened or
    • Any T3 tumours < 5cm from the anal verge
  • Primary resection unlikely to achieve clear margins
  • No previous chemotherapy or radiotherapy for rectal cancer
  • Bone marrow function: absolute neutrophil count ≥1.5 x109/l and platelet count >100 x109/l
  • Hepatobiliary function: serum bilirubin <1.5 x upper limit of normal (ULN); serum ALP <5 x ULN; serum transaminase (AST or ALT) <2.5 x ULN
  • Renal function: Serum creatinine clearance >50mL/min by either Cockcroft-Gault formula or EDTA (ethylenediaminetetraacetic acid) clearance
  • ECOG PS(Eastern Cooperative Oncology Group Performance Status) 0-1
  • Disease can be encompassed within a radical radiotherapy treatment volume
  • No pre-existing condition which would deter radiotherapy, e.g. fistulas, severe ulcerative colitis, Crohn's disease, prior adhesions
  • For women of child-bearing potential a negative pregnancy test is required and adequate contraceptive precautions such as a condom for their partner must be used. For men - adequate contraception must be used.
  • Fit to receive all study treatments
  • Able to comply with oral medication and protocol
  • Signed, written and dated informed consent.
  • Life expectancy ≥ 3 months.

Exc Criteria:

  • Concurrent uncontrolled medical illness, or other previous/current malignant disease likely to interfere with protocol treatments
  • Age<18
  • Any pregnant, lactating women or potentially childbearing patients not using adequate contraception
  • Previous chemotherapy or radiotherapy for rectal cancer
  • Metastatic disease
  • ECOG PS>1
  • Patients who have very significant small bowel delineated within the radiation fields.
  • Current or impending rectal obstruction (unless defunctioning stoma present), metallic colonic rectal stent in situ
  • Pelvic sepsis.
  • Uncontrolled cardiac, respiratory or other disease, or any serious medical or psychiatric disorder that would preclude trial therapy or informed consent.
  • Cardiac conditions as follows:

    • Uncontrolled hypertension (resting BP ≥150/95mmHg despite optimal therapy)
    • Heart failure NYHA Class II or above
    • Prior or current cardiomyopathy
    • Atrial fibrillation with heart rate >100 bpm
    • Unstable ischaemic heart disease
  • Refractory nausea and vomiting, chronic gastrointestinal diseases, or significant bowel resection that would preclude adequate absorption of trial drug
  • Patients who are deemed unsuitable for surgery because of co-morbidity or coagulation problems.
  • Recent (<14 days) major thoracic or abdominal surgery prior to entry into the study or a surgical incision that is not fully healed which would prevent administration of study treatment
  • Known DPD (dihydropyrimidine dehydrogenase)deficiency
  • Patients suffering from any condition that may affect the absorption of capecitabine or IMP (investigational medical product)
  • Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have Hep B, Hep C or HIV
  • Mean QTc with Bazetts correction >470msec in screening ECG or history of familial long QT syndrome

EXC CRITERIA (AZD6244 cohorts)

  • KRAS (Kirsten ras sarcoma viral oncogene) wild-type
  • Prior treatment with a MEK inhibitor
  • Baseline LVEF (left ventricular ejection fraction) ≤50%

EXC CRITERIA (Cediranib cohorts)

  • Known hypersensitivity to Cediranib or any of its excipients
  • Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein < 1.5g in a 24 hr period or protein/creatinine ratio < 1.5.
  • Significant haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks)
  • APTT ratio > 1.5 x ULN
  • Arterial thromboembolic event (including ischemic attack) in the previous 12 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01160926

Locations
United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Sponsors and Collaborators
Christie Hospital NHS Foundation Trust
Cancer Research UK
AstraZeneca
Investigators
Principal Investigator: Mark P Saunders, MBBS The Christie NHS Foundation Trust
  More Information

No publications provided

Responsible Party: Suzanne Rowland, Clinical Trial Project Manager, Christie Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT01160926     History of Changes
Other Study ID Numbers: 09_DOG03_184, 2009-016524-31
Study First Received: July 7, 2010
Last Updated: October 11, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Christie Hospital NHS Foundation Trust:
rectal cancer
capecitabine
radiotherapy
AZD6244
MEK inhibitor
AZD2171
Cediranib
VEGFR inhibitor
FLT-PET (fluoro-l-pyrimidine positron emission tomography)
DCE-MRI (dynamic contrast enhanced magnetic resonance imaging)

Additional relevant MeSH terms:
Capecitabine
Cediranib
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014